GLP-1 treatment exclusions and cautions for adults in Las Vegas
Some medical histories rule out particular GLP-1 medicines; others require additional evaluation. This guide separates labeled contraindications from precautions so you can prepare accurate questions for a licensed prescriber.
Medical histories that prevent use of specific GLP-1 medicines
The prescribing information for Wegovy, Zepbound and Foundayo lists a personal or family history of medullary thyroid carcinoma (MTC), or a diagnosis of multiple endocrine neoplasia syndrome type 2 (MEN 2), as contraindications. These are specific diagnoses. An underactive thyroid or a relative with a different thyroid cancer does not establish the same exclusion, although the exact history still needs review.
A previous serious allergic reaction to the medicine or its ingredients also prevents use of that product. This differs from nausea after an injection. Severe gastroparesis, a condition in which the stomach empties abnormally slowly, is another important distinction: these three products are not recommended for people with it. Changing to one of the oral GLP-1 tablets does not remove its labeled warnings.
GLP-1 treatment for weight loss should not continue during pregnancy. Contact the prescriber promptly if pregnancy occurs; Wegovy, Zepbound and Foundayo labeling directs discontinuation for weight reduction. A planned pregnancy needs an advance medication plan. Decisions about treatment for another medical condition require the treating clinician. The guide to weight loss for women covers reproductive considerations alongside ongoing care.
Absolute
The screening
What the screening actually asks
Family history
Thyroid cancer and endocrine syndromes in particular. If you are unsure, it is worth asking relatives before the appointment rather than guessing.
Personal history
Pancreatitis, gallbladder disease, severe gastrointestinal conditions and any previous reaction to a GLP-1.
Current medication
Especially diabetes treatment, thyroid medication and anything with strict absorption timing.
Pregnancy and planning
Whether pregnancy is possible now or planned, and what contraception is in place.
Care, not exclusion
Health problems that need a more detailed prescribing decision
A previous episode of pancreatitis, gallbladder disease, kidney problems or diabetic eye disease needs a specific conversation about the proposed medicine. These histories do not all carry the same label restriction, and an online checklist cannot determine your individual risk. Bring records of the diagnosis, treatment and any ongoing symptoms. Persistent vomiting or diarrhea can cause dehydration and kidney injury; severe, persistent abdominal pain needs prompt evaluation. The serious side effects guide describes warning symptoms. A physician-supervised program should address how new symptoms will be assessed, including when another specialist needs to be involved.
A complete medication list can change the decision even when your weight and health conditions suggest treatment may help. Insulin and sulfonylureas can increase low blood sugar risk with these medicines; some oral medicines need extra monitoring because absorption may change. Include supplements, other weight loss products and the date of any recent GLP-1 dose. The drug interactions page explains why these details matter. Tell the team about planned anesthesia or deep sedation, too. Neither a favorable GLP-1 eligibility result nor previous tolerance replaces a current product-specific review.
Previous poor reactionSlower titration
Pancreas or gallbladderCloser watch
GI conditionsCase by case
Safety
The rest of the safety picture
Side effects, interactions and what to do about each.
Questions about medical exclusions before starting GLP-1 treatment
Thyroid diagnoses, uncertain family history, breastfeeding and past reactions need different answers.
No. The contraindications for Wegovy, Zepbound and Foundayo identify personal or family MTC and a diagnosis of MEN 2. Other thyroid problems still deserve review, but they are not interchangeable with those diagnoses. Bring the exact condition and current treatment; the broader eligibility guide explains how health history fits the decision.
Say that the history is unknown. If possible, ask relatives about the exact cancer type or endocrine syndrome and bring available records. A relative with MEN 2 also warrants a discussion about your own risk. Do not guess on a screening form or interpret missing information as a negative result.
No. Breastfeeding is not recommended during Wegovy tablet treatment, and Foundayo is not recommended for nursing women. Wegovy injection and Zepbound labeling calls for weighing breastfeeding benefits, maternal clinical need and possible infant risks. Limited milk data do not establish infant safety. Discuss the exact formulation with your prescriber rather than treating all GLP-1 medications alike.
Yes. For weight reduction, Wegovy should be stopped at least two months before a planned pregnancy. Zepbound advises a non-oral contraceptive method or an added barrier method for four weeks after starting and each dose increase; Foundayo specifies 30 days. These are product-specific instructions. Your clinician should plan contraception and any treatment change before you start.
Do not restart that product on your own. A previous serious reaction to the medicine or its ingredients is different from the common digestive side effects and may be a contraindication. Tell the clinician exactly what happened and whether you needed emergency treatment. Trouble breathing or swelling of the face, tongue or throat requires emergency care.
